Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Annals of hematology

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.
PMID: 29943159
Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8.

The original version of this article contained a mistake. The name of Eirini Katroditou should have been Eirini Katodritou. The original article has been corrected.

Cite
Katodritou E, Kyrtsonis MC, Delimpasi S, et al. Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018;97(9):1747doi: 10.1007/s00277-018-3404-8.
Katodritou, E., Kyrtsonis, M. C., Delimpasi, S., Kyriakou, D., Symeonidis, A., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, A., Kioumi, A., Zikos, P., Aktypi, A., Briasoulis, E., Megalakaki, A., Repousis, P., Adamopoulos, I., Gogos, D., Kotsopoulou, M., Pappa, V., Papadaki, E., Fotiou, D., Nikolaou, E., Giannopoulou, E., Hatzimichael, E., Giannakoulas, N., Douka, V., Kokoviadou, K., Timotheatou, D., & Terpos, E. (2018). Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Annals of hematology, 97(9), 1747. https://doi.org/10.1007/s00277-018-3404-8
Katodritou, Eirini, et al. "Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival." Annals of hematology vol. 97,9 (2018): 1747. doi: https://doi.org/10.1007/s00277-018-3404-8
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8. PMID: 29943159; PMCID: PMC6828143.
Copy Download .nbib Format: NLM
Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era.

Mediterranean journal of hematology and infectious diseases

Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, Vourtsi A, Antoniades M, Gkirkas K, Tzouvara E, Katis F, Prokopiou C, Tziotziou I, Balta A, Lemissiou E, Tsirigotis P, Repoussis P, Harhalakis N.
PMID: 22220250
Mediterr J Hematol Infect Dis. 2011;3(1):e2011053. doi: 10.4084/MJHID.2011.053. Epub 2011 Nov 28.

Acute promyelocytic leukemia (APL) is highly curable with the combination of all-transretinoic acid (ATRA) and anthracycline based chemotherapy, but the percentage of early deaths remains high. In the present study, we report the clinical, immunophenotypic, cytogenetic and molecular characteristics...

Cite
Pagoni M, Garofalaki M, Panitsas F, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis. 2011;3(1):e2011053doi: 10.4084/MJHID.2011.053.
Pagoni, M., Garofalaki, M., Panitsas, F., Manola, K., Psarra, K., Economopoulos, P., Vourtsi, A., Antoniades, M., Gkirkas, K., Tzouvara, E., Katis, F., Prokopiou, C., Tziotziou, I., Balta, A., Lemissiou, E., Tsirigotis, P., Repoussis, P., & Harhalakis, N. (2011). Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterranean journal of hematology and infectious diseases, 3(1), e2011053. https://doi.org/10.4084/MJHID.2011.053
Pagoni, Maria, et al. "Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era." Mediterranean journal of hematology and infectious diseases vol. 3,1 (2011): e2011053. doi: https://doi.org/10.4084/MJHID.2011.053
Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, Vourtsi A, Antoniades M, Gkirkas K, Tzouvara E, Katis F, Prokopiou C, Tziotziou I, Balta A, Lemissiou E, Tsirigotis P, Repoussis P, Harhalakis N. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis. 2011;3(1):e2011053. doi: 10.4084/MJHID.2011.053. Epub 2011 Nov 28. PMID: 22220250; PMCID: PMC3248330.
Copy Download .nbib Format: NLM
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.

Journal of clinical medicine

Terpos E, Repousis P, Lalayanni C, Hatjiharissi E, Assimakopoulou T, Vassilopoulos G, Pouli A, Spanoudakis E, Michalis E, Pangalis G, Ntanasis-Stathopoulos I, Poziopoulos C, Kyrtsonis MC, Pappa V, Symeonidis A, Georgopoulos C, Zikos PM, Gavriatopoulou M, Papadaki HA, Dadakaridou M, Karvounis-Marolachakis K, Katodritou E.
PMID: 33916376
J Clin Med. 2021 Apr 05;10(7). doi: 10.3390/jcm10071509.

The "POWERFUL" multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to the approved label after...

Cite
Terpos E, Repousis P, Lalayanni C, et al. Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. J Clin Med. 2021;10(7)doi: 10.3390/jcm10071509.
Terpos, E., Repousis, P., Lalayanni, C., Hatjiharissi, E., Assimakopoulou, T., Vassilopoulos, G., Pouli, A., Spanoudakis, E., Michalis, E., Pangalis, G., Ntanasis-Stathopoulos, I., Poziopoulos, C., Kyrtsonis, M. C., Pappa, V., Symeonidis, A., Georgopoulos, C., Zikos, P. M., Gavriatopoulou, M., Papadaki, H. A., Dadakaridou, M., Karvounis-Marolachakis, K., & Katodritou, E. (2021). Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. Journal of clinical medicine, 10(7), . https://doi.org/10.3390/jcm10071509
Terpos, Evangelos, et al. "Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study." Journal of clinical medicine vol. 10,7 (2021). doi: https://doi.org/10.3390/jcm10071509
Terpos E, Repousis P, Lalayanni C, Hatjiharissi E, Assimakopoulou T, Vassilopoulos G, Pouli A, Spanoudakis E, Michalis E, Pangalis G, Ntanasis-Stathopoulos I, Poziopoulos C, Kyrtsonis MC, Pappa V, Symeonidis A, Georgopoulos C, Zikos PM, Gavriatopoulou M, Papadaki HA, Dadakaridou M, Karvounis-Marolachakis K, Katodritou E. Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. J Clin Med. 2021 Apr 05;10(7). doi: 10.3390/jcm10071509. PMID: 33916376; PMCID: PMC8038613.
Copy Download .nbib Format: NLM
Prematurity, subclinical intraamniotic infection, and fetal biophysical parameters: is there a correlation?.

Infectious diseases in obstetrics and gynecology

Cox SM, Roberts S, Roussis P, Campbell BA, Curry TE.
PMID: 18475321
Infect Dis Obstet Gynecol. 1993;1(2):76-81. doi: 10.1155/S1064744993000183.

OBJECTIVE: This prospective study was undertaken to examine the effects of subclinical intraamniotic infection on fetal behavioral patterns.METHODS: Amniotic fluid was obtained from four groups of patients (n = 99): group 1, patients with preterm premature rupture of the...

Cite
Cox SM, Roberts S, Roussis P, et al. Prematurity, subclinical intraamniotic infection, and fetal biophysical parameters: is there a correlation?. Infect Dis Obstet Gynecol. 1993;1(2):76-81doi: 10.1155/S1064744993000183.
Cox, S. M., Roberts, S., Roussis, P., Campbell, B. A., & Curry, T. E. (1993). Prematurity, subclinical intraamniotic infection, and fetal biophysical parameters: is there a correlation?. Infectious diseases in obstetrics and gynecology, 1(2), 76-81. https://doi.org/10.1155/S1064744993000183
Cox, S M, et al. "Prematurity, subclinical intraamniotic infection, and fetal biophysical parameters: is there a correlation?." Infectious diseases in obstetrics and gynecology vol. 1,2 (1993): 76-81. doi: https://doi.org/10.1155/S1064744993000183
Cox SM, Roberts S, Roussis P, Campbell BA, Curry TE. Prematurity, subclinical intraamniotic infection, and fetal biophysical parameters: is there a correlation?. Infect Dis Obstet Gynecol. 1993;1(2):76-81. doi: 10.1155/S1064744993000183. PMID: 18475321; PMCID: PMC2364297.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries